Companies leading trial announce Kevzara failed to meet primary and secondary endpoints in critically ill COVID-19 patients, so the trial has been halted.
List view / Grid view
Filter the results
The European Investment Bank (EIB), in partnership with the European Commission (EC), have pledged an additional €4.9 billion for use in the global coronavirus response funds.
CanSino Biologics' Ad5-nCoV vaccine, a potential COVID-19 prophylactic, has been approved for study in a Phase I clinical trial in China.
Gilead has announced that the potential COVID-19 drug remdesivir will cost $390 per vial for developed countries, with treatment courses costing $2,340 per patient.
Indian authorities have given the green light to test Bharat Biotech's COVID-19 vaccine in Phase I and Phase II clinical trials.
A study has found that chemotherapy and surgery do not correlate with worse COVID-19 outcomes for cancer patients, whereas taking immune checkpoint inhibitors does.
Dr Madhav Durbha explains the importance of implementing and ensuring stable supply chains to deliver potential COVID-19 vaccines.
Catalent's biologics facility will conduct large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate.
The EMA's human medicines committee (CHMP) has recommended a conditional marketing authorisation for Veklury (remdesivir) to treat COVID-19.
The founder of Apple Steve Jobs once said, “Great things in business are never done by one person; they’re done by a team of people.” This is true now more than ever as medical device manufacturers and companies from a range of industries work together in the fight against COVID-19.…
New findings have revealed that over 2,000 clinical trials are being conducted to test COVID-19 therapies while 583 companies are involved in treatment and vaccine development.
A Phase I clinical trial to test Imperial College London's COVID-19 vaccine candidate has been initiated, with the first patient dosed.
A new consortium has been formed for the study of COVID-19 vaccines after their approval, to monitor their safety and efficacy.
Gilead Sciences has said it will initiate clinical trials in August to test an inhaled formulation of remdesivir, a potential COVID-19 therapy.
Following the successful treatment of a COVID-19 patient with ARDS using ruxolitinib, Germany is set to begin clinical trials to test the drug.